The University of Chicago Header Logo

Connection

Gregory Karczmar to Middle Aged

Back to Details
This is a "connection" page, showing publications Gregory Karczmar has written about Middle Aged.
Gregory Karczmar
Connection Strength
0.967
Middle Aged
  1. Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology. 2022 02; 302(2):368-377.
    View in: PubMed
    Score: 0.055
  2. A compact solution for estimation of physiological parameters from ultrafast prostate dynamic contrast enhanced MRI. Phys Med Biol. 2019 08 07; 64(15):155012.
    View in: PubMed
    Score: 0.047
  3. Low-dose imaging technique (LITE) MRI: initial experience in breast imaging. Br J Radiol. 2019 Nov; 92(1103):20190302.
    View in: PubMed
    Score: 0.046
  4. Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI. Tomography. 2019 06; 5(2):260-265.
    View in: PubMed
    Score: 0.046
  5. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018 10; 53(10):609-615.
    View in: PubMed
    Score: 0.044
  6. Comparison of arterial input functions measured from ultra-fast dynamic contrast enhanced MRI and dynamic contrast enhanced computed tomography in prostate cancer patients. Phys Med Biol. 2018 01 30; 63(3):03NT01.
    View in: PubMed
    Score: 0.042
  7. Kinetic Analysis of Benign and Malignant Breast Lesions With Ultrafast Dynamic Contrast-Enhanced MRI: Comparison With Standard Kinetic Assessment. AJR Am J Roentgenol. 2016 Nov; 207(5):1159-1166.
    View in: PubMed
    Score: 0.038
  8. Ultrafast Bilateral DCE-MRI of the Breast with Conventional Fourier Sampling: Preliminary Evaluation of Semi-quantitative Analysis. Acad Radiol. 2016 09; 23(9):1137-44.
    View in: PubMed
    Score: 0.037
  9. Arterial input functions (AIFs) measured directly from arteries with low and standard doses of contrast agent, and AIFs derived from reference tissues. Magn Reson Imaging. 2016 Feb; 34(2):197-203.
    View in: PubMed
    Score: 0.036
  10. B1 and T1 mapping of the breast with a reference tissue method. Magn Reson Med. 2016 Apr; 75(4):1565-73.
    View in: PubMed
    Score: 0.035
  11. Comparison of dynamic contrast-enhanced MRI parameters of breast lesions at 1.5 and 3.0?T: a pilot study. Br J Radiol. 2015 May; 88(1049):20150021.
    View in: PubMed
    Score: 0.034
  12. Hybrid multidimensional T(2) and diffusion-weighted MRI for prostate cancer detection. J Magn Reson Imaging. 2014 Apr; 39(4):781-8.
    View in: PubMed
    Score: 0.031
  13. Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
    View in: PubMed
    Score: 0.029
  14. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol. 2011 Dec; 18(12):1467-74.
    View in: PubMed
    Score: 0.027
  15. Pure ductal carcinoma in situ: kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade. Radiology. 2007 Dec; 245(3):684-91.
    View in: PubMed
    Score: 0.021
  16. Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging. 2006 Dec; 24(6):1311-5.
    View in: PubMed
    Score: 0.019
  17. High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
    View in: PubMed
    Score: 0.018
  18. Breast MR imaging with high spectral and spatial resolutions: preliminary experience. Radiology. 2002 Aug; 224(2):577-85.
    View in: PubMed
    Score: 0.014
  19. Comparing Radiologist Performance in Diagnosing Clinically Significant Prostate Cancer with Multiparametric versus Hybrid Multidimensional MRI. Radiology. 2022 11; 305(2):399-407.
    View in: PubMed
    Score: 0.014
  20. Physically implausible signals as a quantitative quality assessment metric in prostate diffusion-weighted MR imaging. Abdom Radiol (NY). 2022 07; 47(7):2500-2508.
    View in: PubMed
    Score: 0.014
  21. Revisiting quantitative multi-parametric MRI of benign prostatic hyperplasia and its differentiation from transition zone cancer. Abdom Radiol (NY). 2019 06; 44(6):2233-2243.
    View in: PubMed
    Score: 0.012
  22. Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. AJR Am J Roentgenol. 2019 08; 213(2):W66-W75.
    View in: PubMed
    Score: 0.011
  23. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. AJR Am J Roentgenol. 2019 02; 212(2):351-356.
    View in: PubMed
    Score: 0.011
  24. Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate. AJR Am J Roentgenol. 2019 01; 212(1):124-129.
    View in: PubMed
    Score: 0.011
  25. Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med. 2019 03; 81(3):2147-2160.
    View in: PubMed
    Score: 0.011
  26. Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. J Magn Reson Imaging. 2019 05; 49(5):1374-1380.
    View in: PubMed
    Score: 0.011
  27. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density. Acad Radiol. 2019 07; 26(7):e141-e149.
    View in: PubMed
    Score: 0.011
  28. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 03 15; 25(6):1786-1794.
    View in: PubMed
    Score: 0.011
  29. Fast Temporal Resolution Dynamic Contrast-Enhanced MRI: Histogram Analysis Versus Visual Analysis for Differentiating Benign and Malignant Breast Lesions. AJR Am J Roentgenol. 2018 10; 211(4):933-939.
    View in: PubMed
    Score: 0.011
  30. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol. 2018 09; 211(3):595-604.
    View in: PubMed
    Score: 0.011
  31. Performance of T2 Maps in the Detection of Prostate Cancer. Acad Radiol. 2019 01; 26(1):15-21.
    View in: PubMed
    Score: 0.011
  32. Diagnosis of Prostate Cancer with Noninvasive Estimation of Prostate Tissue Composition by Using Hybrid Multidimensional MR Imaging: A Feasibility Study. Radiology. 2018 06; 287(3):864-873.
    View in: PubMed
    Score: 0.011
  33. Performance of Ultrafast DCE-MRI for Diagnosis of Prostate Cancer. Acad Radiol. 2018 03; 25(3):349-358.
    View in: PubMed
    Score: 0.010
  34. Value of breast MRI for patients with a biopsy showing atypical ductal hyperplasia (ADH). J Magn Reson Imaging. 2017 12; 46(6):1738-1747.
    View in: PubMed
    Score: 0.010
  35. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.009
  36. Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging. 2015 Oct; 40(7):2523-8.
    View in: PubMed
    Score: 0.009
  37. High-resolution diffusion-weighted imaging of the prostate. AJR Am J Roentgenol. 2014 Jul; 203(1):85-90.
    View in: PubMed
    Score: 0.008
  38. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014 May; 21(5):569-77.
    View in: PubMed
    Score: 0.008
  39. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
    View in: PubMed
    Score: 0.008
  40. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40.
    View in: PubMed
    Score: 0.007
  41. Comparing post-operative human breast specimen radiograph and MRI in lesion margin and volume assessment. J Appl Clin Med Phys. 2012 Nov 08; 13(6):3802.
    View in: PubMed
    Score: 0.007
  42. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90.
    View in: PubMed
    Score: 0.007
  43. High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging. 2011 Oct; 34(4):956-61.
    View in: PubMed
    Score: 0.007
  44. The diverse pathology and kinetics of mass, nonmass, and focus enhancement on MR imaging of the breast. J Magn Reson Imaging. 2011 Jun; 33(6):1382-9.
    View in: PubMed
    Score: 0.007
  45. Normal parenchymal enhancement patterns in women undergoing MR screening of the breast. Eur Radiol. 2011 Jul; 21(7):1374-82.
    View in: PubMed
    Score: 0.006
  46. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol. 2010 Oct 07; 55(19):N473-85.
    View in: PubMed
    Score: 0.006
  47. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010 Dec; 257(3):715-23.
    View in: PubMed
    Score: 0.006
  48. Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT. Magn Reson Med. 2010 Jun; 63(6):1601-9.
    View in: PubMed
    Score: 0.006
  49. Relating dose of contrast media administered to uptake and washout of malignant lesions on DCEMRI of the breast. Acad Radiol. 2010 Jan; 17(1):24-30.
    View in: PubMed
    Score: 0.006
  50. Kinetic curves of malignant lesions are not consistent across MRI systems: need for improved standardization of breast dynamic contrast-enhanced MRI acquisition. AJR Am J Roentgenol. 2009 Sep; 193(3):832-9.
    View in: PubMed
    Score: 0.006
  51. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
    View in: PubMed
    Score: 0.006
  52. Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9.
    View in: PubMed
    Score: 0.006
  53. Evaluation of diffusion-weighted MR imaging for detection of bowel inflammation in patients with Crohn's disease. Acad Radiol. 2009 May; 16(5):597-603.
    View in: PubMed
    Score: 0.006
  54. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.005
  55. DCEMRI of breast lesions: is kinetic analysis equally effective for both mass and nonmass-like enhancement? Med Phys. 2008 Jul; 35(7):3102-9.
    View in: PubMed
    Score: 0.005
  56. Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: a sensitivity and specificity study. Magn Reson Med. 2008 Apr; 59(4):747-54.
    View in: PubMed
    Score: 0.005
  57. Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magn Reson Imaging. 2007 Jun; 25(5):593-603.
    View in: PubMed
    Score: 0.005
  58. Anatomical and functional brain imaging using high-resolution echo-planar spectroscopic imaging at 1.5 Tesla. NMR Biomed. 2005 Jun; 18(4):235-41.
    View in: PubMed
    Score: 0.004
  59. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
    View in: PubMed
    Score: 0.004
  60. Hepatic cancers and their response to chemoembolization therapy. Quantitative image-guided 31P magnetic resonance spectroscopy. Invest Radiol. 1992 Jun; 27(6):456-64.
    View in: PubMed
    Score: 0.002
  61. Image-guided 31P magnetic resonance spectroscopy of normal and transplanted human kidneys. Kidney Int. 1990 Aug; 38(2):294-300.
    View in: PubMed
    Score: 0.002
  62. Non-invasive quantitation of human liver metabolites using image-guided 31P magnetic resonance spectroscopy. NMR Biomed. 1990 Feb; 3(1):17-22.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.